ADK Knockout A549 Polyclonal Cells

Product Type:
Polyclonal Cell Population
Species:
Homo sapiens (Human)
Tissue Source:
Lung
Disease:
Lung adenocarcinoma

Datasheet

CRISPR/Cas9-edited polyclonal knockout cell population targeting adenosine kinase (ADK) in A-549 human lung adenocarcinoma cells. Disruption of ADK elevates intracellular and extracellular adenosine, which activates adenosine receptors (ADORA1, ADORA2A, ADORA2B, ADORA3) to modulate cAMP and AMPK signaling, perturb purine homeostasis, and alter methionine cycle flux. Ideal for investigating adenosine-mediated immune evasion, metabolic reprogramming, and receptor pharmacology in non-small cell lung cancer models. Suitable for adenosine quantification, receptor expression analysis, cAMP/AMPK assays, drug sensitivity screening, and metabolomics profiling.

Inquire Now

In stock

Ships next business day

Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice

Disclaimer:

For Research Use Only

Characteristics

Host Cell

A549

Sex of Donor

Male

Age

58 years

Derived From Site

Lung

Gene Name

ADK

Gene Identifier

NCBI Gene ID 132

Storage

Liquid nitrogen (LN2)
Culture Conditions

Growth medium

MEM

Supplement(s)

10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

Temperature

37°C

Atmosphere

5% CO₂
Quality Control

Sterility testing

The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Mycoplasma testing

Negative for mycoplasma through PCR analysis
Disclaimer

Intended Use

This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

Disclaimer

Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

ADK Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the adenosine kinase (ADK) gene in the A-549 human lung adenocarcinoma model.

This engineered model provides a powerful tool for interrogating adenosine-dependent signaling networks without the influence of functional ADK, which normally catalyzes the phosphorylation of adenosine to AMP.

The polyclonal nature of the knockout population preserves the inherent cellular heterogeneity of the parental line while ensuring loss-of-function across the bulk culture, enabling robust and reproducible investigation of adenosine accumulation and its downstream consequences.

Researchers can leverage this model to dissect the role of ADK in purine metabolism and adenosine receptor signaling in a lung cancer context, with broad applicability to studies of metabolic dysregulation, immune modulation, and therapeutic resistance.